Oxford

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • In November 2023, Cabaletta announced the Company’s fourth IND application for CABA-201 was cleared by the FDA for a Phase 1/2 study in patients with generalized myasthenia gravis (gMG).
  • Cabaletta will present new preclinical data for CABA-201 in a poster presentation and Cabaletta Bio Scientific Advisory Board members Carl June, M.D., and Georg Schett, M.D.
  • Cabaletta plans to participate in the following upcoming investor conferences:
    Stifel 2023 Healthcare Conference, which is being held from November 14-15, 2023 in New York, NY.
  • As of September 30, 2023, Cabaletta had cash, cash equivalents and short-term investments of $164.4 million, compared to $106.5 million as of December 31, 2022.

The words that helped wrongly convict Kathleen Folbigg

Retrieved on: 
Wednesday, November 8, 2023

[…]

Key Points: 
  • […]

    Prosecutor: In relation to Laura […] her cause of death was consistent with smothering?

  • Prosecutor: And that she probably died from an acute catastrophic asphyxiating event of unknown causes?
  • 746-48)
    Prosecutor: Are you able to say whether or not Caleb died from a catastrophic asphyxiating event of unknown causes?
  • But there are good reasons for forensic medicine practitioners and advocates to rethink their understanding – and use – of these words.
  • Read more:
    How 'witch-hunts' and 'Stockholm syndrome' became part of political language (and what it has to do with wrestling)

The semantic journey of asphyxia

  • Predictably, this meaning “stoppage of pulse” then sprouted the meaning “stoppage of respiration” – a lack of breath is a salient sign of lifelessness.
  • Subsequently, the path has been rocky, and it is now understood variously by forensic doctors around the world.
  • What is agreed, however, is that “asphyxia” is not a diagnosis; it is not a condition that can be pointed at or diagnosed.

More murkiness

  • As used by experts, this is synonymous with “may or may not mean”.
  • Research shows, however, that people without expert knowledge hear the phrase as strong confirmation of the proposed connection.
  • Clearly, we can’t assume people today would automatically understand “consistent with” as simply a way of saying what is proposed is possible.

Bad meanings drive out good

  • The meanings we carry around in our heads seem so natural we fail to realise other people can have quite different understandings.
  • And the more unusual a word is, the more its meanings will vary because we aren’t given the same opportunities to refine our hypotheses.
  • All three meanings are out there, and different dictionaries favour different ones.

Asphyxia permeated Kathleen Folbigg’s trial

  • (Two pinpoint scratches on Sarah’s lower lip were agreed to be of no significance).
  • This was probably heard by the jury as indicating no injuries meant an “asphyxial event” had occurred – in other words, the children had been strangled or smothered.
  • Known as Meadows Law, this inference stalked Kathleen Folbigg’s trial and her subsequent appeals relentlessly.
  • All of this is medically incoherent and incapable of establishing anything of significance – but probably had a powerful effect on the jury.

'The wisdom of the crowd’

  • In forensic pathology, it encompasses a number of concepts and is used variously by pathologists – and these uses are out of alignment with common lay usage.
  • The jury system relies on “the wisdom of the crowd”.


Professor Cordner was an expert witness at both Commissions of Inquiry into the convictions of Kathleen Folbigg. Kate Burridge does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Oxford Lane Capital Corp. Announces Net Asset Value and Selected Financial Results for the Second Fiscal Quarter and Notes its Previously Announced Distributions on Common Stock for the Months Ending January 31, February 29, and March 31, 2024

Retrieved on: 
Wednesday, November 1, 2023

We provide information relating to Core NII (a non-GAAP measure) on a supplemental basis.

Key Points: 
  • We provide information relating to Core NII (a non-GAAP measure) on a supplemental basis.
  • This measure is not provided as a substitute for GAAP NII, but in addition to it.
  • Our non-GAAP measures may differ from similar measures by other companies, even in the event of similar terms being utilized to identify such measures.
  • The following table provides a reconciliation of GAAP NII to Core NII for the three months ended September 30, 2023:

Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases

Retrieved on: 
Wednesday, November 1, 2023

Since 2020, the companies have collaborated on the development of programs exploring potentially first-in-class, small molecule immunometabolism-targeting therapies, including SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.

Key Points: 
  • Since 2020, the companies have collaborated on the development of programs exploring potentially first-in-class, small molecule immunometabolism-targeting therapies, including SIT-011, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases.
  • A second candidate, SIT-047, a one-carbon metabolism program, continues to be progressed by Sitryx in collaboration with Lilly.
  • Lilly retains its option to exclusively license this second program for future development and commercialisation.
  • We believe in the potential of Sitryx's immunometabolism-targeting therapies to change the treatment paradigm for patients with chronic autoimmune and inflammatory diseases.

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Retrieved on: 
Friday, November 3, 2023

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).

Key Points: 
  • Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).
  • “With over 1 billion people worldwide affected by these conditions, the potential to help reduce the pressure on healthcare systems and patients is immense.
  • We are proud to be leading the way in this field and are excited to move forward with the upcoming Phase III trial to further investigate the potential of this novel compound on top of standard of care including empagliflozin."
  • Hyperkalemia occurred at a rate typical for a CKD population,1 and most episodes did not require medical treatment or BI 690517 discontinuation.1

Fresh Puerto Rican Tostones and Stone Crab Highlight New Caribbean Menu on Holland America Line

Retrieved on: 
Friday, October 27, 2023

SEATTLE, Oct. 27, 2023 /PRNewswire/ -- Fresh, local flavors lead the way for Holland America Line's award-winning cuisine on Caribbean sailings with new regionally themed menus in the Dining Room and Lido Market. Adding to the culinary journey, Caribbean-bound guests can now enjoy a new themed brunch, indulge in local rum tastings, and savor a traditional, pirate-inspired rum punch crafted by renowned mixologist David Wondrich, who also will share his expertise on a March cruise aboard Zaandam.

Key Points: 
  • Offered on sea days, all dishes on the new Caribbean Brunch menu in the Dining Room showcase fresh, local ingredients.
  • "Even traditional Holland America Line favorites, like our bread pudding and crepe bar, will embrace Caribbean flavors with new variations in Lido Market."
  • Made fresh daily with plantain chips, Puerto Rican Tostones are served open-faced for breakfast, lunch and dinner.
  • For more information about Holland America Line, consult a travel advisor, call 1-877-SAIL HAL (877-724-5425) or visit hollandamerica.com .

Advanced Glazings Ltd. Launches "Better Buildings for Humans" Podcast

Retrieved on: 
Monday, October 23, 2023

Sydney, Nova Scotia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Advanced Glazings Ltd. (“AGL”), creator of Solera® and Solera Wall®, and experts in state of the art glass solutions that greatly enhance the lives of building occupants, today announces the launch of the Better Buildings for Humans Podcast (“BBFH”). BBFH aims to revolutionize the discourse surrounding architectural innovation and is dedicated above all to exploring the profound impact of building design on human health, wellness, productivity, and lifestyle.

Key Points: 
  • “BBFH” is a new podcast exploring the vital relationship between buildings and human health, wellness, productivity and lifestyle, produced by Advanced Glazings Ltd., leaders in manufacturing and marketing sustainable and commercially viable technologies related to sunlight
    Sydney, Nova Scotia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Advanced Glazings Ltd .
  • (“AGL”), creator of Solera® and Solera Wall®, and experts in state of the art glass solutions that greatly enhance the lives of building occupants, today announces the launch of the Better Buildings for Humans Podcast (“BBFH”).
  • AGL has deep roots in architectural innovation, originating from the Advanced Glazing Lab and the Solar Thermal Lab at the University of Waterloo in 1996.
  • Stay tuned for riveting discussions, groundbreaking ideas, and unparalleled insights that will shape the future of architecture and building innovation.

Bupa UK to cover EpiSwitch® CiRT for customers with cancer

Retrieved on: 
Wednesday, October 18, 2023

Under this new agreement between Bupa and OBD, Bupa health insurance customers who are being considered for immunotherapy with an anti-PD-1/L1 ICI will be offered the CiRT test, ensuring their doctor receives state-of-the-art personalized guidance to inform their treatment plan.

Key Points: 
  • Under this new agreement between Bupa and OBD, Bupa health insurance customers who are being considered for immunotherapy with an anti-PD-1/L1 ICI will be offered the CiRT test, ensuring their doctor receives state-of-the-art personalized guidance to inform their treatment plan.
  • The CiRT test will also be available to doctors considering treating Bupa customers with an ICI, where decisions need to be made in the face of potential serious illness and lack of response to treatment.
  • Tim Woodman, Medical Director at Bupa UK Insurance, said: “We’re very pleased to launch our partnership with Oxford BioDynamics which will give our customers a leap in confidence when navigating complex decisions about their therapy.
  • Gaining reimbursement from the UK’s leading health insurer is another milestone for the Company, as well as for Bupa customers and their doctors.

How smaller businesses can become net-zero influencers and enablers

Retrieved on: 
Tuesday, October 17, 2023

Cafes and restaurants are also addressing food-related emissions with carbon labelling schemes and more sustainable menu choices.

Key Points: 
  • Cafes and restaurants are also addressing food-related emissions with carbon labelling schemes and more sustainable menu choices.
  • Recruiting smaller businesses to support the drive for net zero makes a lot of sense.
  • But the decarbonisation of smaller firms has only recently attracted serious attention from policymakers, through initiatives such as the UK Business Climate Hub.
  • However, as highlighted in a recent study I worked on with colleagues at Oxford and Sheffield Hallam universities, smaller businesses can also help cut emissions as behavioural “influencers” and “enablers” of change.

Persistent challenges and hopeful signs

    • But all businesses could benefit from a more joined-up support framework to help them achieve their goals.
    • By contrast, smaller businesses in England have not had access to a national funding programme for building energy efficiency.
    • This generates cost and confusion for many smaller businesses as they struggle to find the right support.

Taking SMEs more seriously

    • But while Skidmore mentions SMEs, there are three key areas where more radical change is needed to help them make a real impact on the UK’s decarbonisation goals: 1.
    • Information and signposting The review proposed a “Help to Grow Green” campaign, offering information, resources and vouchers for SMEs to plan and invest in the net-zero transition.
    • The UK government’s Department for Energy Security and Net Zero is piloting a new digital energy advice service to help SMEs navigate the maze of competing information sources.
    • Energy efficiency Skidmore also called for SMEs to be included in tax reforms to accelerate uptake of energy-efficient technologies.

Raman spectroscopy market to grow by USD 287.28 million from 2022 to 2027 | The rising focus on drug discovery and development to boost market growth- Technavio

Retrieved on: 
Friday, October 13, 2023

The potential growth difference for the Raman spectroscopy market between 2022 and 2027 is USD 287.28 million.

Key Points: 
  • The potential growth difference for the Raman spectroscopy market between 2022 and 2027 is USD 287.28 million.
  • Buy the full report here
    The rising focus on drug discovery and development is the key factor driving market growth.
  • Thus, the increase in drug discovery and development will drive the demand for Raman spectroscopy, which will boost the growth of the market during the forecast period.
  • The global atomic spectroscopy market size is estimated to grow by USD 2,214.33 million at a CAGR of 7.02% between 2022 and 2027.